PubMed=8035608
Lambrechts A.C., Dorssers L.C.J., Hupkes P.E., van Gurp R.J.H.L.M., Baumgarten R., Hagemeijer A., van 't Veer M.B., Touw I.P.
Genomic organization of the translocations (8;14) and (14;18) in a new lymphoma cell line.
Leukemia 8:1164-1171(1994)

PubMed=8558920
Dirks W.G., Zaborski M., Jager K., Challier C., Shiota M., Quentmeier H., Drexler H.G.
The (2;5)(p23;q35) translocation in cell lines derived from malignant lymphomas: absence of t(2;5) in Hodgkin-analogous cell lines.
Leukemia 10:142-149(1996)

DOI=10.1016/B978-0-12-221970-2.50457-5
Drexler H.G.
The leukemia-lymphoma cell line factsbook.
(In book) ISBN 9780122219702; pp.1-733; Academic Press; London; United Kingdom (2001)

PubMed=20664054; DOI=10.1182/blood-2009-12-257378; PMCID=PMC2981542
Pham L.V., Tamayo A.T., Li C.-P., Bueso-Ramos C.E., Ford R.J. Jr.
An epigenetic chromatin remodeling role for NFATc1 in transcriptional regulation of growth and survival genes in diffuse large B-cell lymphomas.
Blood 116:3899-3906(2010)

PubMed=20889926; DOI=10.1182/blood-2010-06-290437; PMCID=PMC3037744
Pham L.V., Fu L.-C., Tamayo A.T., Bueso-Ramos C.E., Drakos E., Vega-Vazquez F., Medeiros L.J., Ford R.J. Jr.
Constitutive BR3 receptor signaling in diffuse, large B-cell lymphomas stabilizes nuclear factor-kappaB-inducing kinase while activating both canonical and alternative nuclear factor-kappaB pathways.
Blood 117:200-210(2011)

PubMed=26727417; DOI=10.3109/10428194.2015.1108414
Drexler H.G., Eberth S., Nagel S., MacLeod R.A.F.
Malignant hematopoietic cell lines: in vitro models for double-hit B-cell lymphomas.
Leuk. Lymphoma 57:1015-1020(2016)

PubMed=29416618; DOI=10.18632/oncotarget.20378; PMCID=PMC5787470
Liu W., Chen J., Tamayo A.T., Ruan C.-G., Li L., Zhou S.-H., Shen C., Young K.H., Westin J., Davis R.E., Hu S.-M., Medeiros L.J., Ford R.J. Jr., Pham L.V.
Preclinical efficacy and biological effects of the oral proteasome inhibitor ixazomib in diffuse large B-cell lymphoma.
Oncotarget 9:346-360(2018)

PubMed=29666304; DOI=10.1158/1078-0432.CCR-17-3004
Pham L.V., Huang S.-J., Zhang H., Zhang J., Bell T., Zhou S.-H., Pogue E., Ding Z.-Y., Lam L., Westin J., Davis R.E., Young K.H., Medeiros L.J., Ford R.J. Jr., Nomie K., Zhang L., Wang M.
Strategic therapeutic targeting to overcome venetoclax resistance in aggressive B-cell lymphomas.
Clin. Cancer Res. 24:3967-3980(2018)